CA2306155A1 - Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps - Google Patents
Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps Download PDFInfo
- Publication number
- CA2306155A1 CA2306155A1 CA002306155A CA2306155A CA2306155A1 CA 2306155 A1 CA2306155 A1 CA 2306155A1 CA 002306155 A CA002306155 A CA 002306155A CA 2306155 A CA2306155 A CA 2306155A CA 2306155 A1 CA2306155 A1 CA 2306155A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- carbon atoms
- bromophenyl
- quinazolinyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
This invention provides a method of treating or inhibiting colonic polyps in a mammal in need thereof which comprises administering to said mammal a compound having formula (I), wherein X is phenyl which is optionally substituted; R and R1 are each independently, hydrogen, halogen, alkyl, alkoxy, hydroxy or trifluoromethyl; R2 is hydrogen, alkyl, alkoxy, hydroxy or trifluoromethyl; Y is a radical selected from the group consisting of formulae (II), (III), (IV), (V), (VI), (VII) and (VIII). R3 is independently hydrogen, alkyl, carboxy, carboalkoxy, phenyl, or carboalkyl; n = 2-4; or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y may be the same or different.
Description
WO 99/24037 PCTNS9$/23549 USE OF QUINAZOLINE DERIUATIUES AS TYROSINE KINASE INHIBITORS FOR TREATING
COLONIC POLYPS
This invention relates to the use of certain quinazoline compounds in the 5 treatment and inhibition of colonic polyps.
Colonic Polyps occur in both a familial pattern (Familial Adenomatous Polyps (FAP) and sporadically. FAP afflicts approximately 25,000 patients in the US:
while it is estimated that sporadic adenomatous polyps (SAP) occur in approximately 2 million 10 people per year in the US alone. All these patients are at risk for developing adenocarcinoma of the colon. In the case of FAP, that risk is virtually 100%
and these patients usually undergo a colectomy at an early age. Patients with sporadic polyps are treated with polypectomy and require periodic colonoscopic exar~fination because of their inherent risk of developing recurrent polyps. In fact, parents and siblings of these 15 patients are also at increased risk for developing colorectal cancer.
The genetic basis for FAP has been linked to the presence of mutations in the APC gene. Similar APC mutations have been found in patients with sporadic polyps.
Biochemically, the APC mutation occurs in conjunction with the increased expression of cyclooxygenase enzymes, particularly COX-2. These enzymes are essential for the 20 production of prostenoids, (prostaglandin's; (PG's)) that mediate a number of functions in the bowel including motility, vascular tone, angiogenesis and mucosal protection. PG's are also purported to discourage apoptosis and this is proposed as an explanation for polyp formation.
The therapy of FAP and SAP has focused on inhibiting COX enzymes.
25 Considerable evidence exists for the efficacy of COX inhibitors in reducing polyp formation. These COX inhibitors are predominantly NSAID's such as clinoril, sulindac, piroxicam and etodoloc, all of which appear to be equivalent in their action. A
major problem with NSAID therapy has been the development of serious side effects including peptic ulceration, and cholestatic hepatitis and renal papillary necrosis. Long 30 term therapy with NSAIDs for the treatment of polyps is therefore considered to be impractical.
It has recently been proposed that the activation and overexpression of COX-2 in adenomatous polyps is due to activation of the epidermal growth factor receptor (EGFR). EGFR stimulation by one of it's ligands - amphiregulin (AR), induces the 35 nuclear targeting of COX-2, release of PG's and subsequent mitogenesis, in polarized colonic epithelial cells. COX-2 inhibitors have been shown to prevent this series of events.
DESCRIPTION OF THE INVENTION
5 This invention provides a method of treating or inhibiting colonic polyps in a mammal in need thereof which comprises administering to said mammal a compound of formula 1:
H R HN'X
Y II N ~ ~N
R~
10 wherein:
X is phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, amino, and alkanoylamino of 1-15 6 carbon atoms;
R and R1 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, or trifluoromethyl;
R2 is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl;
20 Y is a radical selected from the group consisting of R Rs Rs Rs , , _ ,Rs , R3 R3 - ~ R3 , R3 R3 R R R~R
COLONIC POLYPS
This invention relates to the use of certain quinazoline compounds in the 5 treatment and inhibition of colonic polyps.
Colonic Polyps occur in both a familial pattern (Familial Adenomatous Polyps (FAP) and sporadically. FAP afflicts approximately 25,000 patients in the US:
while it is estimated that sporadic adenomatous polyps (SAP) occur in approximately 2 million 10 people per year in the US alone. All these patients are at risk for developing adenocarcinoma of the colon. In the case of FAP, that risk is virtually 100%
and these patients usually undergo a colectomy at an early age. Patients with sporadic polyps are treated with polypectomy and require periodic colonoscopic exar~fination because of their inherent risk of developing recurrent polyps. In fact, parents and siblings of these 15 patients are also at increased risk for developing colorectal cancer.
The genetic basis for FAP has been linked to the presence of mutations in the APC gene. Similar APC mutations have been found in patients with sporadic polyps.
Biochemically, the APC mutation occurs in conjunction with the increased expression of cyclooxygenase enzymes, particularly COX-2. These enzymes are essential for the 20 production of prostenoids, (prostaglandin's; (PG's)) that mediate a number of functions in the bowel including motility, vascular tone, angiogenesis and mucosal protection. PG's are also purported to discourage apoptosis and this is proposed as an explanation for polyp formation.
The therapy of FAP and SAP has focused on inhibiting COX enzymes.
25 Considerable evidence exists for the efficacy of COX inhibitors in reducing polyp formation. These COX inhibitors are predominantly NSAID's such as clinoril, sulindac, piroxicam and etodoloc, all of which appear to be equivalent in their action. A
major problem with NSAID therapy has been the development of serious side effects including peptic ulceration, and cholestatic hepatitis and renal papillary necrosis. Long 30 term therapy with NSAIDs for the treatment of polyps is therefore considered to be impractical.
It has recently been proposed that the activation and overexpression of COX-2 in adenomatous polyps is due to activation of the epidermal growth factor receptor (EGFR). EGFR stimulation by one of it's ligands - amphiregulin (AR), induces the 35 nuclear targeting of COX-2, release of PG's and subsequent mitogenesis, in polarized colonic epithelial cells. COX-2 inhibitors have been shown to prevent this series of events.
DESCRIPTION OF THE INVENTION
5 This invention provides a method of treating or inhibiting colonic polyps in a mammal in need thereof which comprises administering to said mammal a compound of formula 1:
H R HN'X
Y II N ~ ~N
R~
10 wherein:
X is phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, amino, and alkanoylamino of 1-15 6 carbon atoms;
R and R1 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, or trifluoromethyl;
R2 is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl;
20 Y is a radical selected from the group consisting of R Rs Rs Rs , , _ ,Rs , R3 R3 - ~ R3 , R3 R3 R R R~R
R3 ~ R3 R R3 ~
R , R 3 , and 3 3 \
R R3 R3 ~C~R3)2)n R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms;
n = 2-4;
or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y may be 5 the same or different.
The pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, malefic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly 10 known acceptable acids.
The alkyl portion of the alkyl, alkoxy, carboalkoxy, carboalkyl, and alkanoylamino substituents include both straight chain as well as branched carbon chains, e.g. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-15 pentyl or n-hexyl. Carboxy is defined as a -C02H radical. Carboalkoxy of 2-7 carbon atoms is defined as a -C02R" radical, where R" is an alkyl radical of 1-6 carbon atoms. Carboalkyl is defined as a -COR" radical, where R" is an alkyl radical of 1-6 carbon atoms. When used herein the term halogen refers to chlorine, bromine, iodine or fluorine. When X is substituted, it is preferred that it is mono- , di- , or tri-20 substituted, with monosubstituted being most preferred. When a compound of this invention contains an assymetric center, this invention covers the individual R and S
entantiomers as well as the racemate with respect to such compound.
Of the compounds of this invention, preferred members include those in which 25 R, R~, and R2 are hydrogen; and those in which R, R~, and R2 are hydrogen and X is phenyl either unsubstituted or monosubstituted with halogen or alkyl of 1-6 carbon atoms. One group of compounds within the invention are those wherein X is monosubstituted in the 3-position, preferably by a halogen, more preferably by bromine. A further group of compounds within the invention are those wherein Y
is 30 -CH=CH-C02H, -CH=CH-C02Et, -CH=C(Me)2, -CH=CH-Et, -CH=CH-CH3, -CH=CH-CH=CH-CH3~ -CH=CH2, -CH=CH-Ph, -CH~CH-CH3 or 2-cyclo-pentene. R3 is preferably hydrogen, methyl, ethyl, phenyl, C02H or C02Et.
R , R 3 , and 3 3 \
R R3 R3 ~C~R3)2)n R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms;
n = 2-4;
or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y may be 5 the same or different.
The pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, malefic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly 10 known acceptable acids.
The alkyl portion of the alkyl, alkoxy, carboalkoxy, carboalkyl, and alkanoylamino substituents include both straight chain as well as branched carbon chains, e.g. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-15 pentyl or n-hexyl. Carboxy is defined as a -C02H radical. Carboalkoxy of 2-7 carbon atoms is defined as a -C02R" radical, where R" is an alkyl radical of 1-6 carbon atoms. Carboalkyl is defined as a -COR" radical, where R" is an alkyl radical of 1-6 carbon atoms. When used herein the term halogen refers to chlorine, bromine, iodine or fluorine. When X is substituted, it is preferred that it is mono- , di- , or tri-20 substituted, with monosubstituted being most preferred. When a compound of this invention contains an assymetric center, this invention covers the individual R and S
entantiomers as well as the racemate with respect to such compound.
Of the compounds of this invention, preferred members include those in which 25 R, R~, and R2 are hydrogen; and those in which R, R~, and R2 are hydrogen and X is phenyl either unsubstituted or monosubstituted with halogen or alkyl of 1-6 carbon atoms. One group of compounds within the invention are those wherein X is monosubstituted in the 3-position, preferably by a halogen, more preferably by bromine. A further group of compounds within the invention are those wherein Y
is 30 -CH=CH-C02H, -CH=CH-C02Et, -CH=C(Me)2, -CH=CH-Et, -CH=CH-CH3, -CH=CH-CH=CH-CH3~ -CH=CH2, -CH=CH-Ph, -CH~CH-CH3 or 2-cyclo-pentene. R3 is preferably hydrogen, methyl, ethyl, phenyl, C02H or C02Et.
A process for the preparation of a compound of Formula 1 as defined above which comprises:
a) reducing a 6-amino-4-anilinoquinazoline of Formula 6 wherein R, R 1, R2 and 5 X are as defined above R HN~x H2N \ ~ N
J
R~
a) reducing a 6-amino-4-anilinoquinazoline of Formula 6 wherein R, R 1, R2 and 5 X are as defined above R HN~x H2N \ ~ N
J
R~
with:
i) an acid chloride of Formula 7, wherein Y is as defined above //O
Y~C I
15 ii) a mixed anhydride of Formula 8, wherein Y is as defined above O
r ~OCORa or iii) a cyclic anhydride of Formula 11 wherein each R5 is independently 20 hydrogen, phenyl, or alkyl of 1-6 carbon atoms O
O
~~ O
b) reacting a compound of Formula 17 wherein R, R1, R2 and Y are as defined 25 above and Hal is any suitable halogen R Hal Y II N ~ ~N
o ~ ~ NJ
Rp with an aniline of Formula 18 wherein X is as defined above or c) reacting a compound of Formula 24 wherein R, R 1, R2 and Y are as defined above R
YuN ~ C N
R2 ~ N~N(CH3)2 R~
with an aniline of Formula 25 wherein X is as defined above.
The preparation of the compounds of this invention encompassed by Formula 9 is described below in Flowsheet A where R, R1, R2, R3, X, and n are as defined above 20 and R4 is alkyl of 1-6 carbon atoms (preferably isobutyl). Y' is a radical selected from the group consisting of:
R R3 R3 Rs, s~ R, _ R ~ ~ ~~--(~ s 3 ' ' R 3 , R3 Rs R s Rs R~a R3 R's R~s Rs~ ~ R3 Ra _--R~3 , and R3 ~ Rs C R' fig R g ~ ~ 3)2)n wherein each R'3 is independently alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms. According to the 5 sequence of reaction outlined in flowsheet A, a 5-vitro-anthranilonitrile of Formula 2 is heated at about 100°C with or without solvent containing an excess of dimethylformamide dimethyl acetal to furnish an amidine of Formula 3 . Heating a solution of amidine 3 and the aniline 4 in acetic acid for 1 to S hours gives the 6-nitro-4-anilinoquinazolines of Formula 5. Reduction of the vitro group of 5 using a 10 reducing agent such as iron in an acetic acid-alcohol mixture at elevated temperature gives the 6-amino-4-anilinoquinazolines of Formula 6 . Acylation of 6 with either an acid chloride of Formula 7 or a mixed anhydride of Formula 8 (which is prepared from the corresponding carboxylic acid) in an inert solvent such as tetrahydrofuran (THF) in the presence of an organic base such as pyridine or triethylamine gives the compounds 15 of this invention represented by Formula 9. In those cases where 7 or 8 have an asymmetric carbon atom, they can be used as the racemate or as the individual R or S
entantiomers in which case the compounds of this invention will be in the racemic or R
and S optically active forms, respectively. The 5-vitro-anthranilonitriles of Formula 2 needed to prepare the compounds of this invention are either already known to the art or 20 can be prepared by procedures known in the art as detailed in the following references:
Baudet, RecLTrav.Chim.Pays-Bas, 43, 710 ( 1924); Hartmans, Recl.Trav.Chim.Pays-Bas, 65, 468, 469 (1946) ; Taylor et al., J.Amer.Chem.Soc., 82, 6058,6063 (1960);
Taylor et al., J.Amer.Chem.Soc., 82, 3152,3154 (1960); Deshpande; Seshadri, Indian J.Chem., 11 , 538 (1973); Katritzky, Alan R.; Laurenzo, Kathieen S., J.Org.Chem., 25 51 (1986); Niclas, Hans-Joachim; Bohle, Matthias; Rick, Jens-Detlev;
Zeuner,Frank;
Zoelch, Lothar, Z.Chem., 25(4), 137-138 (1985).
WO 99/24037 PCT/US9$/23549 _ '7 _ FLOWSHEET A
02N I ~ CN (CH3)2NCH(OCH3)2 02N \ CN
I / ~ CHg O
R2 / NH2 DMF RZ N N(CH3)2 R~ Rt R HN'X R HN'X
O 2N ~ ~ N Fe H2N \ ~ N
I / J CH3C02H, C2H50H~ I /
R2 ~ ~ N R2 N
R~ Ri O ~~O
// ,X
°r OCOR4 H R HN
7 8 ~~N \ ~N
THF, pyridine, or (C2Hs)3N O I /
R~
The preparation of the compounds of this invention encompassed by Formula 12 is described below in Flowsheet B wherein R, R1, R2, X, and n are described above. Each RS is independently hydrogen, phenyl, or alkyl of 1-6 carbon atoms.
5 According to the reaction outlined in Flowsheet B, the 6-amino-4-anilinoquinazolines of Formula 10 (prepared as in Flowsheet A) are acylated with a cyclic anhydride of Formula 11 in an inert solvent such as tetrahydrofuran in the presence of a basic catalyst such as pyridine or triethylamine.
-g_ FLOWSHEET B
O
O
R HN'X R5 R5 R5 ~ R HN'X
~N 11 H02C~ ~ ~N
- , p ~ NJ THF, pyridine, or (C2H5)3N R2 N
R~ R~
Representative compounds of this invention were evaluated in several standard pharmacological test procedures that showed that the compounds of this invention possess significant activity as inhibitors of protein tyrosine kinases, and are S antiproliferative agents. Based on the activity shown in the standard pharmacological test procedures, the compounds of this invention are therefore useful as antineoplastic agents. The test procedures used and results obtained are shown below.
The preparation of the compounds of this invention encompassed by Formula 10 19 is described below in Flowsheet C wherein Y', R4, and X are described above.
According to the reactions outlined in Flowsheet C, 4-choro-6-nitroquinazoline, 13, (Morley, JS. and Simpson,J. Chem.. Soc., 360 ( 1948)) is reduced to 6-amino-4-chloroquinazoline, 14, using a reducing agent such as sodium hydrosulfite in a two phase system consisting of tetrahydrofuran and water in the presence of a small amount 15 of phase transfer catalyst. Acylation of 14 with either an acid chloride of Formula 15 or a mixed anhydride of Formula 16 (which is prepared from the corresponding carboxylic acid) in an inert solvent such as tetrahydrofuran (THF) in the presence of an organic base such as pyridine or N-methyl morpholine gives the compounds of Formula 17. In those cases where 15 or lb have an asymmetric carbon atom, they can 20 be used as the racemate or as the individual R or S entantiomers in which case the compounds of this invention will be in the racemic or R and S optically active forms, respectively. Heating a compound of Formula 17 with an aniline of Formula 18, in a inert solvent such as isopropanol, gives the compounds of this invention represented by Formula 19.
FLOWSHEET C
I
I
02N ~ ~ N Na2S204, (C8H»)sNCH3+ CI' H2N I ~ ~ N
NJ THF, H20 / NJ
Y'---~ or Y ~OCOR CI
CI
~ X-NH2 15 16 Y~~ ~ ~N 18 'O I / N J (CH3jpCHOH
THF, pyridine, or N-methyl morpholine H H N~
Y~~N ~ ~ N
o ~ / NJ
The preparation of the compounds of this invention encompassed by Formula 5 26 is described below in Flowsheet D wherein Y', Rq., and X are described above.
According to the reactions outlined in Flowsheet D, the nitro group of 20 (prepared as in Flowsheet A) is reduced to the corresponding amino compound 21 using a palladium catalyst and a source of hydrogen which can be hydrogen itself or cyclohexene.
Acylation of 21 with either an acid chloride of Formula 22 or a mixed anhydride of 10 Formula 23 (which is prepared from the corresponding carboxylic acid) in an inert solvent such as tetrahydrofuran (THF) in the presence of an organic base such as pyridine or N-methyl morpholine gives the compounds of Formula 24. In those cases where 22 or 23 have an asymmetric carbon atom, they can be used as the racemate or as the individual R or S entantiomers in which case the compounds of this invention will be in the racemic or R and S optically active forms, respectively.
Heating a compound of Formula 24 with an aniline of Formula 25, in a inert solvent such as acetic acid gives the compounds of this invention represented by Formula 26.
FLOWSHEET D
02N I ~ C N cyclohexene H2N ~ C N
/
/ N~N{CH~)2 CH30H, Pd/C N N(CH3)2 O //O
// Y' Y ~Ci or ~OCOR4 'Y ~ ~ CN
22 ~ O
--~ N N(CH3)2 THF, pyridine, or (C2H5)3N
H2N_X Y N H N'X
25 ~ ~ ~ N
acetic acid O I /
N
The ability of the compounds of this invention to treat or inhibit colonic polyps 10 was demonstrated in an i~ v_ ivo standard pharmacological test procedure as described below. The compound of Example 9 was evaluated in this procedure, which emulates familial adenomatous polyps (FAP) in humans, as a representative compound of this invention. The Min mouse used in this test procedure, currently the best available model for FAP, is a strain which has lost both copies of the APC gene. These animals 15 develop multiple intestinal polyps (Adenomas) that ultimately progress to form adenocarcinomas. The polyps that develop in Min mice express EGFR and have activated COX-2. NSAID's such as sulindac and etodoloc can reduce (but not eradicate) intestinal polyp formulation in these animals indicating that COX-2 and the ultimate production of PG's is likely responsible for these effects. The following briefly describes the procedure used and the results obtained in this standard pharmacological test procedure.
5 The compound of Example 9 was blended with a standard marine chow and animals were given ad libitum access to the food. Based on estimated food consumption, the compound of Example 9 was added at a concentration commensurate with animals ingesting 20 mg/kg/day. At day 30, 4 treated + 4 control (chow alone) animals were sacrificed and assessed for polyp number. All control animals had greater 10 than 30 polyps in their bowel, while the treated animals had none.
Identical results were observed at 60 days - when 15 animals/group were assessed. The control animals had greater than 30 (larger) polyps while the treated animals had none.
These data demonstrate that the compounds of this invention effectively inhibit 15 polyp formation in animals having mutations in their APC genes. Based on the results obtained in this standard pharmacological test procedure, the compounds of this invention are useful in treating or inhibiting the formation of colonic polyps.
The compounds of this invention may formulated neat or may be combined with 20 one or more pharmaceutically acceptable carriers for administration. For example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50%
ethanol, 25 and the like, or parenterally in the form of sterile injectable solution or suspension containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may. contain, for example, from about 0.05 up to about 90% of the active ingredient in combination with the carrier, more usually between about 5 % and 60% by weight.
30 The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 1000 mg/kg of animal body weight, optionally given in divided doses two to four 35 times a day, or in sustained release form. For most large mammals the total daily dosage is from about 1 to 1000 mg, preferably from about 2 to 500 mg. Dosage forms suitable for internal use comprise from about 0.5 to 1000 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier.
This dosage regimen may be adjusted to provide the optimal therapeutic response.
For example, several divided doses may be administered daily or the dose may be 5 proportionally reduced as indicated by the exigencies of the therapeutic situation.
These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, 10 peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
15 The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.
In some cases it may be desirable to administer the compounds directly to the airways in the form of an aerosol.
20 These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary 25 conditions of storage and use, these preparation contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and 30 must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The Garner can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and 35 vegetable oils.
The preparation of representative examples of the compounds of this invention is described below.
Example 1 5 N' (2-Cyano-4-nitrophenyll-N N-dimethylformamidine A 40.8 g portion of 5-vitro-anthranilonitrile and 40 ml of N, N-dimethylformamide dimethyl acetal were heated on a steam bath for 2 hours. The solvents were removed at reduced pressure and the residue was taken up in methyiene 10 chloride. After passing this solution through Magnesol the solvent was removed.
After washing with ether 50.8 g of N'-(2-cyano-4-nitrophenyl)-N,N-dimethyl-formamidine was obtained.
Example 2 15 N-(3-Bromophenvl)-6-vitro-4-quinazolinamine A solution of 23.74 ml of 3-bromo aniline and 40.5 g N'-(2-cyano-4-nitrophenyl)-N,N-dimethylformamidine in 100 ml of glacial acetic acid was stirred and heated in an oil bath at 148°C for 1.5 hours. On cooling, filtration of the resulting solid 20 gives a quantitative yield of N-(3-bromophenyl)-6-vitro-4-quinazolinamine:
mp = 267-270°C; mass spectrum (m/e): 345.
Example 3 N-(3-Bromonhenyrll-4 6-auiyzolig famine A mixture of 34.5 g of N-(3-bromophenyl)-6-vitro-4-quinazolinamine and 16.8 g of iron powder in 150 ml of ethanol and 150 ml of glacial acetic acid was heated in an oil bath at 120°C for 2 hours. After filtration of the solid, solid sodium carbonate was added to the filtrate giving a solid. This was filtered, and the solid was extracted with 30 methanol. The extracts were treated with charcoal and evaporated to a solid. After washing the solid with ether 27.5 g of N-{3-bromophenyl)-4,6-quinazolindiamine was obtained: mass spectrum (m/e): 315.
Example 4 4 ff4 fl3 Brom~henv_1,L)aminol-6-q,~inazolinvlLaminol-4-oxo-(Z)-~-butenoic acid A 15 ml portion of pyridine was added to 1.6 g of N-(3-bromophenyl)-4,6-5 quinazolindiamine and 0.6 g of malefic anhydride. After stirnng overnight, the solvents were removed on the rotary evaporator. The solid was taken up in about 400 ml of hot ethanol and the insoluble material filtered to give 0.33 g of 4-[[4-[(3-Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(Z)-2-butenoic acid: mass spectrum (m/e): M+H 413, 415.
Example 5 4 f~4 f(3 Bromo~hen~laminol6-qu_inazoli ~laminol4-oxo-(E)-2-butenoic acid ethyl se A solution of N-(3-bromophenyl)-4,6-quinazolindiamine in 15 ml of pyridine was cooled in an ice bath and a solution of 1.22 g of ethyl fumaryl chloride in 10 ml of methylene chloride was added dropwise. After stirring for 1.5 hours, the reaction was allowed to come to room temperature. The solvents were removed at reduced pressure 20 and the residue was treated with water. The red solid was filtered and extracted into hot acetone. After filtration of the insoluble material, the filtrate was concentrated to give 0.45 g of 4-[[4-[(3-Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(E)-2-butenoic acid, ethyl ester: mp = 259-263°C, mass spectrum (m/e): M+H
441, 443.
25 Example 6 N f4 fl3-Brom~y~yaminol-6-a~inazoli~rll-3-methyl-2-butenamide A solution of 1.58 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 15 ml of pyridine was cooled in an ice bath and a solution of 0.67 ml of 3,3-dimethylacryloyl 30 chloride in 7 ml of ether was added dropwise. After stirnng and cooling for 2 hours, the solvents were removed at reduced pressure. The residue was treated with water and the resulting solid was recrystallized from methyl cellusolve to give 0.97 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-3-methyl-2-butenamide: mp = 300-301°C, mass spectrum (m/e): 396, 398.
Example 7 N f4 fl3 Bromo~yl)aminol-6-qu~~olinvll-(E)-2-butenamide A solution of 1.6 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 15 ml of 5 pyridine was cooled in an ice bath and a solution of 0.57 ml of trans-crotonoyl chloride in 6 ml of ether was added dropwise. After stirring and cooling for 2 hours, the solvents were removed at reduced pressure. The residue was treated with water and the resulting solid recrystallized from n-butanol to give 0.69 g of N-[4-[(3 bromophenyl)amino]-6-quinazolinyl]-(E)-2-butenamide: mp - 153-160°C, mass 10 spectrum (m/e): M+H 383, 385.
Example 8 N f4 f(3 Bromonhenyl)aminol-6-q~inazolinvll-2-met~yl-2-pronenamide A solution of 1.6 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 15 ml of pyridine was cooled in an ice bath and a solution of 0.59 ml of methacryoyl chloride in 6 ml of ether was added dropwise. After stirring and cooling for 2 hours, the solvents were removed at reduced pressure. The residue was treated with water and the 20 resulting solid was taken up in n-butanol (warming). Addition of ether to the cooled solution gives 0.44 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-methyl-propenamide: mp = 40-245°C, mass spectrum (m/e): M+H 383, 385.
Example 9 25 N f4 f(3-Bromouheny~)aminol-6-quinazolinvll-2-butynamide A solution of 0.50 g of 2-butynoic acid in 10 ml of tetrahydrofuran was cooled in an ice bath. A 0.79 ml portion of isobutyl chlorofolmate followed by a 0.66 ml portion of N-methyl morpholine were added. After about 1 minute a solution of 1.6 g 30 of N-(3-bromophenyl)-4,6-quinazolindiamine in 10 ml of pyridine was added.
The reaction was allowed to come to room temperature and stir overnight. The solvents were removed at reduced pressure and the solid was recrystallized from n-butanol to give 1.07 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide: mass spectrum (m/e): 381, 383.
Example 10 ~[j~, l3-Bromophenvllaminol~quinazolinvllaminol-4-oxo-(E)-2-butenoic acid A 2.5 ml portion of 10 N aqueous sodium hydroxide was added to 2.3 g of 4-[[4-[(3-5 bromophenyl)amino)-6-quinazolinyl]amino]-4-oxo-(E)-2-butenoic acid ethyl ester (Example 5) in 25 ml of ethanol. After stirring for an hour, 2.1 ml of concentrated hydrochloric acid was added, and the reaction was stirred an additional 2 hours. The resulting solid was recrystallized from n-butanol to give 0.97 g of 4-[[4-[(3 Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(E)-2-butenoic acid: mass spectrum 10 (m/e): M+H 413.
Example 11 N f4 fl3 Bromo~he~,~)aminol-6-quinazoliny~,l-2 4-hexadienamide A solution of 0.67g of 2,4-hexadienoic acid in 10 ml of tetrahydrofuran was cooled in an ice bath. A 0.79 ml portion of isobutyl chloroformate followed by a 0.66 ml portion of N-methyl morpholine were added. After about 1 minute a solution of 1.6 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 10 ml of pyridine was added.
The 20 reaction was allowed to come to room temperature and stir overnight. The solvents were removed at reduced pressure and the solid was recrystallized to give 1.0 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2,4-hexadienamide: mp = 258-260°C.
25 Example 12 N-[4-t( -Bromophenyl)aminol-6-auinazolin3r11-2-c3rclo~nteneamide A solution of 0.43 g of 2-cyclopedtenoic acid in Sml of tetrahydrofuran was cooled in an ice bath. A 0.49 ml portion of isobutyl chloroformate followed by a 0.41 30 ml portion of N-methyl morpholine were added. After about 1 minute a solution of 1.0 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 10 ml of pyridine was added.
The reaction was allowed to come to room temperature and stir overnight. Another 0.5 equivalents of mixed anhydride was added. The mixture was stirred for 5 hours.
The solvents were removed at reduced pressure and the solid was purified by chromatography on silica gel to give 0.30 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-cyclopenteneamide: mass spectrum (m/e): 409 (M+H, EI).
Example 13 5 ~1-f4-fl3-Brom~heny~)aminol-6-quinazolinyil-2- r~openamide A solution of 2.0 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 10 ml of pyridine was cooled in an ice bath and a solution of 0.61 ml of acryoyl chloride in 30 ml of ether was added dropwise at 0°C. After stirring at room temperature for 3.5 10 hours, the solvents were removed at reduced pressure. The residue was purified by chromatography to give 0.2 g of N-[4-[(3-bromophenyl)amino)-6-quinazolinyl)-2-propenamide: mass spectrum (m/e): M+H 369.
15 Example 14 ~T-[g-fl3-Bromophen~lamino]-6~- uinazoliny],1~3-phenyl-2-t~rODVnamidel A solution of 0.93 g of 3-phenyl-2-propynoic acid in lOml of tetrahydrofuran was cooled in an ice bath. A 0.82 ml portion of isobutyl chloroformate followed by a 20 0.69 ml portion of N-methyl morpholine were added. After about 1 minute a solution of 1.0 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 7 ml of pyridine was added.
The reaction at 0°C for 1 hr.. The solvents were removed at reduced pressure and the solid was purified by chromatography on silica gel to give 0.01 g of N-[4-[(3 bromophenyl)amino]-6-quinazolinyl]-(3-phenyl-2-propynamide): mass spectrum (m/e):
25 443.2, 445.2 (M+H, electrospray).
Example I5 6-amino-4.-chloroquinazoline 30 A mixture consisting of 3.25 g of 4-chloro-6-nitroquinazoline, 10.8 g of sodium hydrosulfite, and 0.3 g of the phase transfer catalyst (CgH 17)3NCH3+
Cl- in 97 mi of tetrahydrofuran and 32 ml of water was stirred rapidly for 2 hours.
The mixture was diluted with ether and the organic layer was separated. The organic solution was washed with brine and then dried over magnesium sulfate. The solution 35 was passed through a small column of silica gel. The solvent was removed at 30°C at reduced pressure giving 6-amino-4-chloroquinazoline which is used in the next step without additional purification.
Example 16 j4-chloro-6-auinazo]iny]]-2-butvnamide 5 A solution of 1.64 g of 2-butynoic acid in 46 ml of tetrahydrofuran was cooled in an ice bath. A 2.34 ml portion of isobutyl chloroformate followed by a 4.13 ml portion of N-methyl morpholine were added. After about 10 minutes, this was poured into a solution of 6-amino-4-chloroquinazoline in 46 ml tetrahydrofuran. This mixture was stirred at room temperature for 2 hours. The mixture was poured into a mixture of 10 brine and saturated sodium bicarbonate and extracted with ether. The ether solution was dried over magnesium sulfate and filtered. The solvent was removed giving j4-chloro-6-quinazolinyl]-2-butynamide as colored oil that was used in the next step without additional purification.
IS Example 17 I~ [4 fl3-Bromophen~~aminol-~uinazolin~rll-2-but~tnamide A solution consisting of 1.76 g of j4-chloro-6-quinazolinyl]-2-butynamide and 1.23 g of 3-bromo aniline was refluxed under an inert atmosphere in 23 ml of 20 isopropanol for 40 minutes. The mixture was cooled to room temperature and 200 ml of ether was added giving 0.4 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide as the hydrochloride salt. Neutralizing with sodium bicarbonate solution, extracting with ethyl acetate, removal of the solvent, and recyrstallization from 1-butanol gives N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide as the free 25 base.
Example 18 1~'- g Amino-2-c3ranQ,phenylZN N-dimethvlformamidine A solution of 6.0 g (27.5 mmol) of N'-(2-cyano-4-nitrophenyl)-N,N
30 dimethylformamidine, 33.9 g (41.8 ml, 412.4 mmol) of cyclohexene, and 0.6 g of IO% Pd/C in 360 ml of methanol was refluxed for 4 hrs. The hot mixture was filtered through Celite. Solvent was removed and the residue was recrystallized from chloroform-carbon tetrachloride giving 4.9 g (95%) of the title compound as a light gray crystalline solid. mass spectrum (m/e):188.9 (M+H, electrospray).
Example 19 N-[3-Cyapo--4-[[Sdime ~rlamino)methylenelaminol phenvll-2-bu namide To a solution of 2.01 g (23.9 mmol) of 2-butynoic acid and 2.9 ml (22.3 mmol) isobutyl chloroformate in 30 ml tetrahydrofuran was stirred at 0°C under 5 nitrogen as 2.42 g (2.63 ml, 22.3 mmol) of N-methyl morpholine was added over 3 min, After stirring for 15 min., a solution of N'-(4-amino-2-cyanophenyl)-N,N-dimethylfonmamidine and 1.6 g ( 1.75 ml, 15.9 mmol) of N-methyl morpholine in ml tetrahydrofuran was added over 4 min. The mixture was stirred 30 min. at 0°C and 30 min. at room temperature. The mixture was diluted with 70 ml of ethyl acetate and 10 poured into a mixture of brine and saturated sodium bicarbonate. The organic layer was dried (MgS04) and filtered through a pad of silica gel. The solvent was removed and the residue was stirred with 50 ml of ether. The suspended solid was collected to give 3.61 g (89%) of an off white solid. mass spectrum (m/e): 255.0 (M+H, electrospray).
Example 20 ty-~4-i v s-t~romo~nen3rl ~arrnnol-o-qulnazounm i-~-omvnamlae A solution of 3.0 g ( 11.8 mmol) of N-[3-cyano-4-[[(dimethylamino) methylene]amino] phenyl]-2-butynamide and 2.23 g ( 12.98 mmol) of 3-bromo aniline 20 in 18 ml of acetic acid was refluxed gently with stirnng under nitrogen for 1 hr 15 min..
The mixture was cooled in an ice bath and a solid mass formed. The solid was collected by filtration and washed with ether-acetonitrile 1:1 to give a yellow solid which was recrystailized from ethanol giving 2.51 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide : mass spectrum (m/e): 381, 383.
i) an acid chloride of Formula 7, wherein Y is as defined above //O
Y~C I
15 ii) a mixed anhydride of Formula 8, wherein Y is as defined above O
r ~OCORa or iii) a cyclic anhydride of Formula 11 wherein each R5 is independently 20 hydrogen, phenyl, or alkyl of 1-6 carbon atoms O
O
~~ O
b) reacting a compound of Formula 17 wherein R, R1, R2 and Y are as defined 25 above and Hal is any suitable halogen R Hal Y II N ~ ~N
o ~ ~ NJ
Rp with an aniline of Formula 18 wherein X is as defined above or c) reacting a compound of Formula 24 wherein R, R 1, R2 and Y are as defined above R
YuN ~ C N
R2 ~ N~N(CH3)2 R~
with an aniline of Formula 25 wherein X is as defined above.
The preparation of the compounds of this invention encompassed by Formula 9 is described below in Flowsheet A where R, R1, R2, R3, X, and n are as defined above 20 and R4 is alkyl of 1-6 carbon atoms (preferably isobutyl). Y' is a radical selected from the group consisting of:
R R3 R3 Rs, s~ R, _ R ~ ~ ~~--(~ s 3 ' ' R 3 , R3 Rs R s Rs R~a R3 R's R~s Rs~ ~ R3 Ra _--R~3 , and R3 ~ Rs C R' fig R g ~ ~ 3)2)n wherein each R'3 is independently alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms. According to the 5 sequence of reaction outlined in flowsheet A, a 5-vitro-anthranilonitrile of Formula 2 is heated at about 100°C with or without solvent containing an excess of dimethylformamide dimethyl acetal to furnish an amidine of Formula 3 . Heating a solution of amidine 3 and the aniline 4 in acetic acid for 1 to S hours gives the 6-nitro-4-anilinoquinazolines of Formula 5. Reduction of the vitro group of 5 using a 10 reducing agent such as iron in an acetic acid-alcohol mixture at elevated temperature gives the 6-amino-4-anilinoquinazolines of Formula 6 . Acylation of 6 with either an acid chloride of Formula 7 or a mixed anhydride of Formula 8 (which is prepared from the corresponding carboxylic acid) in an inert solvent such as tetrahydrofuran (THF) in the presence of an organic base such as pyridine or triethylamine gives the compounds 15 of this invention represented by Formula 9. In those cases where 7 or 8 have an asymmetric carbon atom, they can be used as the racemate or as the individual R or S
entantiomers in which case the compounds of this invention will be in the racemic or R
and S optically active forms, respectively. The 5-vitro-anthranilonitriles of Formula 2 needed to prepare the compounds of this invention are either already known to the art or 20 can be prepared by procedures known in the art as detailed in the following references:
Baudet, RecLTrav.Chim.Pays-Bas, 43, 710 ( 1924); Hartmans, Recl.Trav.Chim.Pays-Bas, 65, 468, 469 (1946) ; Taylor et al., J.Amer.Chem.Soc., 82, 6058,6063 (1960);
Taylor et al., J.Amer.Chem.Soc., 82, 3152,3154 (1960); Deshpande; Seshadri, Indian J.Chem., 11 , 538 (1973); Katritzky, Alan R.; Laurenzo, Kathieen S., J.Org.Chem., 25 51 (1986); Niclas, Hans-Joachim; Bohle, Matthias; Rick, Jens-Detlev;
Zeuner,Frank;
Zoelch, Lothar, Z.Chem., 25(4), 137-138 (1985).
WO 99/24037 PCT/US9$/23549 _ '7 _ FLOWSHEET A
02N I ~ CN (CH3)2NCH(OCH3)2 02N \ CN
I / ~ CHg O
R2 / NH2 DMF RZ N N(CH3)2 R~ Rt R HN'X R HN'X
O 2N ~ ~ N Fe H2N \ ~ N
I / J CH3C02H, C2H50H~ I /
R2 ~ ~ N R2 N
R~ Ri O ~~O
// ,X
°r OCOR4 H R HN
7 8 ~~N \ ~N
THF, pyridine, or (C2Hs)3N O I /
R~
The preparation of the compounds of this invention encompassed by Formula 12 is described below in Flowsheet B wherein R, R1, R2, X, and n are described above. Each RS is independently hydrogen, phenyl, or alkyl of 1-6 carbon atoms.
5 According to the reaction outlined in Flowsheet B, the 6-amino-4-anilinoquinazolines of Formula 10 (prepared as in Flowsheet A) are acylated with a cyclic anhydride of Formula 11 in an inert solvent such as tetrahydrofuran in the presence of a basic catalyst such as pyridine or triethylamine.
-g_ FLOWSHEET B
O
O
R HN'X R5 R5 R5 ~ R HN'X
~N 11 H02C~ ~ ~N
- , p ~ NJ THF, pyridine, or (C2H5)3N R2 N
R~ R~
Representative compounds of this invention were evaluated in several standard pharmacological test procedures that showed that the compounds of this invention possess significant activity as inhibitors of protein tyrosine kinases, and are S antiproliferative agents. Based on the activity shown in the standard pharmacological test procedures, the compounds of this invention are therefore useful as antineoplastic agents. The test procedures used and results obtained are shown below.
The preparation of the compounds of this invention encompassed by Formula 10 19 is described below in Flowsheet C wherein Y', R4, and X are described above.
According to the reactions outlined in Flowsheet C, 4-choro-6-nitroquinazoline, 13, (Morley, JS. and Simpson,J. Chem.. Soc., 360 ( 1948)) is reduced to 6-amino-4-chloroquinazoline, 14, using a reducing agent such as sodium hydrosulfite in a two phase system consisting of tetrahydrofuran and water in the presence of a small amount 15 of phase transfer catalyst. Acylation of 14 with either an acid chloride of Formula 15 or a mixed anhydride of Formula 16 (which is prepared from the corresponding carboxylic acid) in an inert solvent such as tetrahydrofuran (THF) in the presence of an organic base such as pyridine or N-methyl morpholine gives the compounds of Formula 17. In those cases where 15 or lb have an asymmetric carbon atom, they can 20 be used as the racemate or as the individual R or S entantiomers in which case the compounds of this invention will be in the racemic or R and S optically active forms, respectively. Heating a compound of Formula 17 with an aniline of Formula 18, in a inert solvent such as isopropanol, gives the compounds of this invention represented by Formula 19.
FLOWSHEET C
I
I
02N ~ ~ N Na2S204, (C8H»)sNCH3+ CI' H2N I ~ ~ N
NJ THF, H20 / NJ
Y'---~ or Y ~OCOR CI
CI
~ X-NH2 15 16 Y~~ ~ ~N 18 'O I / N J (CH3jpCHOH
THF, pyridine, or N-methyl morpholine H H N~
Y~~N ~ ~ N
o ~ / NJ
The preparation of the compounds of this invention encompassed by Formula 5 26 is described below in Flowsheet D wherein Y', Rq., and X are described above.
According to the reactions outlined in Flowsheet D, the nitro group of 20 (prepared as in Flowsheet A) is reduced to the corresponding amino compound 21 using a palladium catalyst and a source of hydrogen which can be hydrogen itself or cyclohexene.
Acylation of 21 with either an acid chloride of Formula 22 or a mixed anhydride of 10 Formula 23 (which is prepared from the corresponding carboxylic acid) in an inert solvent such as tetrahydrofuran (THF) in the presence of an organic base such as pyridine or N-methyl morpholine gives the compounds of Formula 24. In those cases where 22 or 23 have an asymmetric carbon atom, they can be used as the racemate or as the individual R or S entantiomers in which case the compounds of this invention will be in the racemic or R and S optically active forms, respectively.
Heating a compound of Formula 24 with an aniline of Formula 25, in a inert solvent such as acetic acid gives the compounds of this invention represented by Formula 26.
FLOWSHEET D
02N I ~ C N cyclohexene H2N ~ C N
/
/ N~N{CH~)2 CH30H, Pd/C N N(CH3)2 O //O
// Y' Y ~Ci or ~OCOR4 'Y ~ ~ CN
22 ~ O
--~ N N(CH3)2 THF, pyridine, or (C2H5)3N
H2N_X Y N H N'X
25 ~ ~ ~ N
acetic acid O I /
N
The ability of the compounds of this invention to treat or inhibit colonic polyps 10 was demonstrated in an i~ v_ ivo standard pharmacological test procedure as described below. The compound of Example 9 was evaluated in this procedure, which emulates familial adenomatous polyps (FAP) in humans, as a representative compound of this invention. The Min mouse used in this test procedure, currently the best available model for FAP, is a strain which has lost both copies of the APC gene. These animals 15 develop multiple intestinal polyps (Adenomas) that ultimately progress to form adenocarcinomas. The polyps that develop in Min mice express EGFR and have activated COX-2. NSAID's such as sulindac and etodoloc can reduce (but not eradicate) intestinal polyp formulation in these animals indicating that COX-2 and the ultimate production of PG's is likely responsible for these effects. The following briefly describes the procedure used and the results obtained in this standard pharmacological test procedure.
5 The compound of Example 9 was blended with a standard marine chow and animals were given ad libitum access to the food. Based on estimated food consumption, the compound of Example 9 was added at a concentration commensurate with animals ingesting 20 mg/kg/day. At day 30, 4 treated + 4 control (chow alone) animals were sacrificed and assessed for polyp number. All control animals had greater 10 than 30 polyps in their bowel, while the treated animals had none.
Identical results were observed at 60 days - when 15 animals/group were assessed. The control animals had greater than 30 (larger) polyps while the treated animals had none.
These data demonstrate that the compounds of this invention effectively inhibit 15 polyp formation in animals having mutations in their APC genes. Based on the results obtained in this standard pharmacological test procedure, the compounds of this invention are useful in treating or inhibiting the formation of colonic polyps.
The compounds of this invention may formulated neat or may be combined with 20 one or more pharmaceutically acceptable carriers for administration. For example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50%
ethanol, 25 and the like, or parenterally in the form of sterile injectable solution or suspension containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may. contain, for example, from about 0.05 up to about 90% of the active ingredient in combination with the carrier, more usually between about 5 % and 60% by weight.
30 The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 1000 mg/kg of animal body weight, optionally given in divided doses two to four 35 times a day, or in sustained release form. For most large mammals the total daily dosage is from about 1 to 1000 mg, preferably from about 2 to 500 mg. Dosage forms suitable for internal use comprise from about 0.5 to 1000 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier.
This dosage regimen may be adjusted to provide the optimal therapeutic response.
For example, several divided doses may be administered daily or the dose may be 5 proportionally reduced as indicated by the exigencies of the therapeutic situation.
These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, 10 peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
15 The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.
In some cases it may be desirable to administer the compounds directly to the airways in the form of an aerosol.
20 These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary 25 conditions of storage and use, these preparation contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and 30 must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The Garner can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and 35 vegetable oils.
The preparation of representative examples of the compounds of this invention is described below.
Example 1 5 N' (2-Cyano-4-nitrophenyll-N N-dimethylformamidine A 40.8 g portion of 5-vitro-anthranilonitrile and 40 ml of N, N-dimethylformamide dimethyl acetal were heated on a steam bath for 2 hours. The solvents were removed at reduced pressure and the residue was taken up in methyiene 10 chloride. After passing this solution through Magnesol the solvent was removed.
After washing with ether 50.8 g of N'-(2-cyano-4-nitrophenyl)-N,N-dimethyl-formamidine was obtained.
Example 2 15 N-(3-Bromophenvl)-6-vitro-4-quinazolinamine A solution of 23.74 ml of 3-bromo aniline and 40.5 g N'-(2-cyano-4-nitrophenyl)-N,N-dimethylformamidine in 100 ml of glacial acetic acid was stirred and heated in an oil bath at 148°C for 1.5 hours. On cooling, filtration of the resulting solid 20 gives a quantitative yield of N-(3-bromophenyl)-6-vitro-4-quinazolinamine:
mp = 267-270°C; mass spectrum (m/e): 345.
Example 3 N-(3-Bromonhenyrll-4 6-auiyzolig famine A mixture of 34.5 g of N-(3-bromophenyl)-6-vitro-4-quinazolinamine and 16.8 g of iron powder in 150 ml of ethanol and 150 ml of glacial acetic acid was heated in an oil bath at 120°C for 2 hours. After filtration of the solid, solid sodium carbonate was added to the filtrate giving a solid. This was filtered, and the solid was extracted with 30 methanol. The extracts were treated with charcoal and evaporated to a solid. After washing the solid with ether 27.5 g of N-{3-bromophenyl)-4,6-quinazolindiamine was obtained: mass spectrum (m/e): 315.
Example 4 4 ff4 fl3 Brom~henv_1,L)aminol-6-q,~inazolinvlLaminol-4-oxo-(Z)-~-butenoic acid A 15 ml portion of pyridine was added to 1.6 g of N-(3-bromophenyl)-4,6-5 quinazolindiamine and 0.6 g of malefic anhydride. After stirnng overnight, the solvents were removed on the rotary evaporator. The solid was taken up in about 400 ml of hot ethanol and the insoluble material filtered to give 0.33 g of 4-[[4-[(3-Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(Z)-2-butenoic acid: mass spectrum (m/e): M+H 413, 415.
Example 5 4 f~4 f(3 Bromo~hen~laminol6-qu_inazoli ~laminol4-oxo-(E)-2-butenoic acid ethyl se A solution of N-(3-bromophenyl)-4,6-quinazolindiamine in 15 ml of pyridine was cooled in an ice bath and a solution of 1.22 g of ethyl fumaryl chloride in 10 ml of methylene chloride was added dropwise. After stirring for 1.5 hours, the reaction was allowed to come to room temperature. The solvents were removed at reduced pressure 20 and the residue was treated with water. The red solid was filtered and extracted into hot acetone. After filtration of the insoluble material, the filtrate was concentrated to give 0.45 g of 4-[[4-[(3-Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(E)-2-butenoic acid, ethyl ester: mp = 259-263°C, mass spectrum (m/e): M+H
441, 443.
25 Example 6 N f4 fl3-Brom~y~yaminol-6-a~inazoli~rll-3-methyl-2-butenamide A solution of 1.58 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 15 ml of pyridine was cooled in an ice bath and a solution of 0.67 ml of 3,3-dimethylacryloyl 30 chloride in 7 ml of ether was added dropwise. After stirnng and cooling for 2 hours, the solvents were removed at reduced pressure. The residue was treated with water and the resulting solid was recrystallized from methyl cellusolve to give 0.97 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-3-methyl-2-butenamide: mp = 300-301°C, mass spectrum (m/e): 396, 398.
Example 7 N f4 fl3 Bromo~yl)aminol-6-qu~~olinvll-(E)-2-butenamide A solution of 1.6 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 15 ml of 5 pyridine was cooled in an ice bath and a solution of 0.57 ml of trans-crotonoyl chloride in 6 ml of ether was added dropwise. After stirring and cooling for 2 hours, the solvents were removed at reduced pressure. The residue was treated with water and the resulting solid recrystallized from n-butanol to give 0.69 g of N-[4-[(3 bromophenyl)amino]-6-quinazolinyl]-(E)-2-butenamide: mp - 153-160°C, mass 10 spectrum (m/e): M+H 383, 385.
Example 8 N f4 f(3 Bromonhenyl)aminol-6-q~inazolinvll-2-met~yl-2-pronenamide A solution of 1.6 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 15 ml of pyridine was cooled in an ice bath and a solution of 0.59 ml of methacryoyl chloride in 6 ml of ether was added dropwise. After stirring and cooling for 2 hours, the solvents were removed at reduced pressure. The residue was treated with water and the 20 resulting solid was taken up in n-butanol (warming). Addition of ether to the cooled solution gives 0.44 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-methyl-propenamide: mp = 40-245°C, mass spectrum (m/e): M+H 383, 385.
Example 9 25 N f4 f(3-Bromouheny~)aminol-6-quinazolinvll-2-butynamide A solution of 0.50 g of 2-butynoic acid in 10 ml of tetrahydrofuran was cooled in an ice bath. A 0.79 ml portion of isobutyl chlorofolmate followed by a 0.66 ml portion of N-methyl morpholine were added. After about 1 minute a solution of 1.6 g 30 of N-(3-bromophenyl)-4,6-quinazolindiamine in 10 ml of pyridine was added.
The reaction was allowed to come to room temperature and stir overnight. The solvents were removed at reduced pressure and the solid was recrystallized from n-butanol to give 1.07 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide: mass spectrum (m/e): 381, 383.
Example 10 ~[j~, l3-Bromophenvllaminol~quinazolinvllaminol-4-oxo-(E)-2-butenoic acid A 2.5 ml portion of 10 N aqueous sodium hydroxide was added to 2.3 g of 4-[[4-[(3-5 bromophenyl)amino)-6-quinazolinyl]amino]-4-oxo-(E)-2-butenoic acid ethyl ester (Example 5) in 25 ml of ethanol. After stirring for an hour, 2.1 ml of concentrated hydrochloric acid was added, and the reaction was stirred an additional 2 hours. The resulting solid was recrystallized from n-butanol to give 0.97 g of 4-[[4-[(3 Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(E)-2-butenoic acid: mass spectrum 10 (m/e): M+H 413.
Example 11 N f4 fl3 Bromo~he~,~)aminol-6-quinazoliny~,l-2 4-hexadienamide A solution of 0.67g of 2,4-hexadienoic acid in 10 ml of tetrahydrofuran was cooled in an ice bath. A 0.79 ml portion of isobutyl chloroformate followed by a 0.66 ml portion of N-methyl morpholine were added. After about 1 minute a solution of 1.6 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 10 ml of pyridine was added.
The 20 reaction was allowed to come to room temperature and stir overnight. The solvents were removed at reduced pressure and the solid was recrystallized to give 1.0 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2,4-hexadienamide: mp = 258-260°C.
25 Example 12 N-[4-t( -Bromophenyl)aminol-6-auinazolin3r11-2-c3rclo~nteneamide A solution of 0.43 g of 2-cyclopedtenoic acid in Sml of tetrahydrofuran was cooled in an ice bath. A 0.49 ml portion of isobutyl chloroformate followed by a 0.41 30 ml portion of N-methyl morpholine were added. After about 1 minute a solution of 1.0 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 10 ml of pyridine was added.
The reaction was allowed to come to room temperature and stir overnight. Another 0.5 equivalents of mixed anhydride was added. The mixture was stirred for 5 hours.
The solvents were removed at reduced pressure and the solid was purified by chromatography on silica gel to give 0.30 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-cyclopenteneamide: mass spectrum (m/e): 409 (M+H, EI).
Example 13 5 ~1-f4-fl3-Brom~heny~)aminol-6-quinazolinyil-2- r~openamide A solution of 2.0 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 10 ml of pyridine was cooled in an ice bath and a solution of 0.61 ml of acryoyl chloride in 30 ml of ether was added dropwise at 0°C. After stirring at room temperature for 3.5 10 hours, the solvents were removed at reduced pressure. The residue was purified by chromatography to give 0.2 g of N-[4-[(3-bromophenyl)amino)-6-quinazolinyl)-2-propenamide: mass spectrum (m/e): M+H 369.
15 Example 14 ~T-[g-fl3-Bromophen~lamino]-6~- uinazoliny],1~3-phenyl-2-t~rODVnamidel A solution of 0.93 g of 3-phenyl-2-propynoic acid in lOml of tetrahydrofuran was cooled in an ice bath. A 0.82 ml portion of isobutyl chloroformate followed by a 20 0.69 ml portion of N-methyl morpholine were added. After about 1 minute a solution of 1.0 g of N-(3-bromophenyl)-4,6-quinazolindiamine in 7 ml of pyridine was added.
The reaction at 0°C for 1 hr.. The solvents were removed at reduced pressure and the solid was purified by chromatography on silica gel to give 0.01 g of N-[4-[(3 bromophenyl)amino]-6-quinazolinyl]-(3-phenyl-2-propynamide): mass spectrum (m/e):
25 443.2, 445.2 (M+H, electrospray).
Example I5 6-amino-4.-chloroquinazoline 30 A mixture consisting of 3.25 g of 4-chloro-6-nitroquinazoline, 10.8 g of sodium hydrosulfite, and 0.3 g of the phase transfer catalyst (CgH 17)3NCH3+
Cl- in 97 mi of tetrahydrofuran and 32 ml of water was stirred rapidly for 2 hours.
The mixture was diluted with ether and the organic layer was separated. The organic solution was washed with brine and then dried over magnesium sulfate. The solution 35 was passed through a small column of silica gel. The solvent was removed at 30°C at reduced pressure giving 6-amino-4-chloroquinazoline which is used in the next step without additional purification.
Example 16 j4-chloro-6-auinazo]iny]]-2-butvnamide 5 A solution of 1.64 g of 2-butynoic acid in 46 ml of tetrahydrofuran was cooled in an ice bath. A 2.34 ml portion of isobutyl chloroformate followed by a 4.13 ml portion of N-methyl morpholine were added. After about 10 minutes, this was poured into a solution of 6-amino-4-chloroquinazoline in 46 ml tetrahydrofuran. This mixture was stirred at room temperature for 2 hours. The mixture was poured into a mixture of 10 brine and saturated sodium bicarbonate and extracted with ether. The ether solution was dried over magnesium sulfate and filtered. The solvent was removed giving j4-chloro-6-quinazolinyl]-2-butynamide as colored oil that was used in the next step without additional purification.
IS Example 17 I~ [4 fl3-Bromophen~~aminol-~uinazolin~rll-2-but~tnamide A solution consisting of 1.76 g of j4-chloro-6-quinazolinyl]-2-butynamide and 1.23 g of 3-bromo aniline was refluxed under an inert atmosphere in 23 ml of 20 isopropanol for 40 minutes. The mixture was cooled to room temperature and 200 ml of ether was added giving 0.4 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide as the hydrochloride salt. Neutralizing with sodium bicarbonate solution, extracting with ethyl acetate, removal of the solvent, and recyrstallization from 1-butanol gives N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide as the free 25 base.
Example 18 1~'- g Amino-2-c3ranQ,phenylZN N-dimethvlformamidine A solution of 6.0 g (27.5 mmol) of N'-(2-cyano-4-nitrophenyl)-N,N
30 dimethylformamidine, 33.9 g (41.8 ml, 412.4 mmol) of cyclohexene, and 0.6 g of IO% Pd/C in 360 ml of methanol was refluxed for 4 hrs. The hot mixture was filtered through Celite. Solvent was removed and the residue was recrystallized from chloroform-carbon tetrachloride giving 4.9 g (95%) of the title compound as a light gray crystalline solid. mass spectrum (m/e):188.9 (M+H, electrospray).
Example 19 N-[3-Cyapo--4-[[Sdime ~rlamino)methylenelaminol phenvll-2-bu namide To a solution of 2.01 g (23.9 mmol) of 2-butynoic acid and 2.9 ml (22.3 mmol) isobutyl chloroformate in 30 ml tetrahydrofuran was stirred at 0°C under 5 nitrogen as 2.42 g (2.63 ml, 22.3 mmol) of N-methyl morpholine was added over 3 min, After stirring for 15 min., a solution of N'-(4-amino-2-cyanophenyl)-N,N-dimethylfonmamidine and 1.6 g ( 1.75 ml, 15.9 mmol) of N-methyl morpholine in ml tetrahydrofuran was added over 4 min. The mixture was stirred 30 min. at 0°C and 30 min. at room temperature. The mixture was diluted with 70 ml of ethyl acetate and 10 poured into a mixture of brine and saturated sodium bicarbonate. The organic layer was dried (MgS04) and filtered through a pad of silica gel. The solvent was removed and the residue was stirred with 50 ml of ether. The suspended solid was collected to give 3.61 g (89%) of an off white solid. mass spectrum (m/e): 255.0 (M+H, electrospray).
Example 20 ty-~4-i v s-t~romo~nen3rl ~arrnnol-o-qulnazounm i-~-omvnamlae A solution of 3.0 g ( 11.8 mmol) of N-[3-cyano-4-[[(dimethylamino) methylene]amino] phenyl]-2-butynamide and 2.23 g ( 12.98 mmol) of 3-bromo aniline 20 in 18 ml of acetic acid was refluxed gently with stirnng under nitrogen for 1 hr 15 min..
The mixture was cooled in an ice bath and a solid mass formed. The solid was collected by filtration and washed with ether-acetonitrile 1:1 to give a yellow solid which was recrystailized from ethanol giving 2.51 g of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide : mass spectrum (m/e): 381, 383.
Claims (9)
1. A method of treating or inhibiting colonic polyps in a mammal in need thereof which comprises administering to said mammal a compound of the formula wherein:
X is phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, amino, and alkanoylamino of 1-6 carbon atoms;
R and R1 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, or trifluoromethyl;
R2 is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl;
Y is a radical selected from the group consisting of R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms;
n = 2-4;
-or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y
may be the same or different.
X is phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, amino, and alkanoylamino of 1-6 carbon atoms;
R and R1 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, or trifluoromethyl;
R2 is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl;
Y is a radical selected from the group consisting of R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms;
n = 2-4;
-or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y
may be the same or different.
2. A method as claimed in Claim 1 wherein R, R1, and R2 are hydrogen or a pharmaceutically acceptable salt thereof.
3. A method as claimed in Claim 1 or Claim 2 wherein X is phenyl unsubstituted or substituted with halogen or alkyl of 1-6 carbon atoms.
4. A method as claimed in any one of Claims 1 to 3 in which N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-methyl-2-propenamide, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2,4-hexadienamide, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-(E)-2-butenamide, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-3-methyl-2-butenamide, 4-[[4-[(3-Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(Z)-2-butenoic acid, 4-[[4-[(3-Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(E)-2-butenoic acid, 4-[[4-[(3-Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(E)-2-butenoic acid, ethyl ester , N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-cyclopentenamide, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-(3-phenyl-2-propynamide) or a pharmaceutically acceptable salt of any of these is administered.
5. Use of a compound of the formula wherein:
X is phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, amino, and alkanoylamino of 1-6 carbon atoms;
R and R1 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, or trifluoromethyl;
R2 is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl;
Y is a radical selected from the group consisting of and R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms;
n = 2-4;
or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y
may be the same or different, in the preparation of a medicament for the treatment or inhibition of colonic polyps in a mammal.
X is phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, amino, and alkanoylamino of 1-6 carbon atoms;
R and R1 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, or trifluoromethyl;
R2 is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl;
Y is a radical selected from the group consisting of and R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms;
n = 2-4;
or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y
may be the same or different, in the preparation of a medicament for the treatment or inhibition of colonic polyps in a mammal.
6. Use as claimed in Claim 5 wherein R, R1, and R2 are hydrogen or a pharmaceutically acceptable salt thereof.
7. Use as claimed in Claim 5 or Claim 6 wherein X is phenyl unsubstituted or substituted with halogen or alkyl of 1-6 carbon atoms.
8. Use as claimed in any one of Claims 5 to 7 in which the compound administered is N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-methyl-2-propenamide, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2,4-hexadienamide, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-(E)-2-butenamide, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-3-methyl-2-butenamide, 4-[[4-[(3-Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(Z)-2-butenoic acid, 4-[[4-[(3-Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(E)-2-butenoic acid, 4-[[4-[(3-Bromophenyl)amino]-6-quinazolinyl]amino]-4-oxo-(E)-2-butenoic acid, ethyl ester, N-[4-((3-bromophenyl)amino]-6-quinazolinyl]-2-cyclopentenamide, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-(3-phenyl-2-propynamide)
9. A pharmaceutical composition for treating or inhibiting colonic polyps in a mammal which comprises a compound of formula 1 as defined in claim 5 and optionally a pharmaceutical carrier.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96508497A | 1997-11-06 | 1997-11-06 | |
| US08/965,084 | 1997-11-06 | ||
| PCT/US1998/023549 WO1999024037A1 (en) | 1997-11-06 | 1998-11-04 | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2306155A1 true CA2306155A1 (en) | 1999-05-20 |
Family
ID=25509419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002306155A Abandoned CA2306155A1 (en) | 1997-11-06 | 1998-11-04 | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1039910A1 (en) |
| JP (1) | JP2001522802A (en) |
| KR (1) | KR20010031813A (en) |
| CN (1) | CN1278176A (en) |
| AR (1) | AR016415A1 (en) |
| AU (1) | AU1308799A (en) |
| BR (1) | BR9814116A (en) |
| CA (1) | CA2306155A1 (en) |
| HU (1) | HUP0004286A3 (en) |
| IL (1) | IL135622A0 (en) |
| NO (1) | NO20002166L (en) |
| NZ (1) | NZ503991A (en) |
| PL (1) | PL340800A1 (en) |
| WO (1) | WO1999024037A1 (en) |
| ZA (1) | ZA9810134B (en) |
Families Citing this family (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02001448A (en) * | 1999-08-12 | 2002-07-02 | American Cyanamid Co | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer. |
| US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| KR101126560B1 (en) | 2003-05-30 | 2012-04-05 | 도꾜 다이가꾸 | Process for predicting drug response |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| KR20080095915A (en) | 2004-05-06 | 2008-10-29 | 워너-램버트 캄파니 엘엘씨 | 4-phenylamino-quinazolin-6-yl-amides |
| CN101124228B (en) | 2004-12-14 | 2011-06-15 | 阿斯利康(瑞典)有限公司 | Pyrazolopyrimidine compounds as antitumor agents |
| WO2006071079A1 (en) * | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| DE602006018331D1 (en) | 2005-09-20 | 2010-12-30 | Astrazeneca Ab | 4- (1H-INDAZOL-5-YLAMINO) CHINAZOLINE COMPOUNDS AS INHIBITORS OF ERBB RECEPTORT ROSINKINASE FOR THE TREATMENT OF CANCER |
| ATE522625T1 (en) | 2006-09-12 | 2011-09-15 | Genentech Inc | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF LUNG CANCER USING PDGFRA, KIT OR KDG GENE AS GENETIC MARKERS |
| EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
| AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
| WO2009092052A2 (en) | 2008-01-18 | 2009-07-23 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating polyps |
| TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
| CA2711582A1 (en) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof |
| JP5739802B2 (en) | 2008-05-13 | 2015-06-24 | アストラゼネカ アクチボラグ | 4- (3-Chloro-2-fluoroanilino) -7-methoxy-6-{[1- (N-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline fumarate |
| US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| JP5539351B2 (en) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them |
| TW201544123A (en) | 2009-03-20 | 2015-12-01 | Genentech Inc | Anti-HER antibodies |
| RU2012124093A (en) | 2009-11-12 | 2013-12-20 | Дженентек, Инк. | METHOD FOR INCREASING DENSITY OF DENDRITIC SPIKES |
| CA2781578A1 (en) | 2010-01-12 | 2011-07-21 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| US9556249B2 (en) | 2010-02-18 | 2017-01-31 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
| MX2012010265A (en) | 2010-03-17 | 2012-10-01 | Hoffmann La Roche | Imidazopyridine and purine compounds, compositions and methods of use. |
| JP2013528787A (en) | 2010-04-16 | 2013-07-11 | ジェネンテック， インコーポレイテッド | FOX03A as a predictive biomarker of the effects of PI3K / AKT kinase pathway inhibitors |
| DK2612151T3 (en) | 2010-08-31 | 2017-10-02 | Genentech Inc | BIOMARKETS AND METHODS OF TREATMENT |
| RU2013114352A (en) | 2010-09-15 | 2014-10-20 | Ф. Хоффманн-Ля Рош Аг | AZABENZENESIAZOLES, COMPOSITIONS AND METHODS OF APPLICATION |
| MX2013005445A (en) | 2010-11-19 | 2013-07-29 | Hoffmann La Roche | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors. |
| WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| CA2843499A1 (en) | 2011-08-12 | 2013-02-21 | F. Hoffmann-La Roche Ag | Indazole compounds, compositions and methods of use |
| CN103890007A (en) | 2011-08-17 | 2014-06-25 | 霍夫曼-拉罗奇有限公司 | Neuregulin antibodies and uses thereof |
| BR112014006643A2 (en) | 2011-09-20 | 2017-04-04 | Hoffmann La Roche | imidazopyridine compounds, compositions and methods of use thereof |
| WO2013081645A2 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
| RU2014136886A (en) | 2012-03-27 | 2016-05-20 | Дженентек, Инк. | DIAGNOSTIC AND TREATMENT TYPES RELATED TO HER3 INHIBITORS |
| CN104994879A (en) | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | Methods of treating cancer and preventing drug resistance |
| JP2016510751A (en) | 2013-03-06 | 2016-04-11 | ジェネンテック， インコーポレイテッド | Methods of treating and preventing anticancer drug resistance |
| US10035801B2 (en) | 2013-03-13 | 2018-07-31 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| CA2903480A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
| BR112015022604A2 (en) | 2013-03-14 | 2017-10-24 | Genentech Inc | Uses of a Chromatin Modifier Modulator and an Egfr Antagonist |
| EP2968537A1 (en) | 2013-03-15 | 2016-01-20 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| RU2016112568A (en) | 2013-09-05 | 2017-10-06 | Дженентек, Инк. | ANTIPROLIFERATIVE COMPOUNDS |
| TW201605857A (en) | 2013-10-03 | 2016-02-16 | 赫孚孟拉羅股份公司 | Therapeutic inhibitors of CDK8 and uses thereof |
| KR20160070136A (en) | 2013-10-18 | 2016-06-17 | 제넨테크, 인크. | Anti-rsp02 and/or anti-rsp03 antibodies and their uses |
| NZ720515A (en) | 2013-12-17 | 2022-12-23 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| CA2934028A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| MA39776A (en) | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| RU2016142476A (en) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | COMBINED THERAPY, INCLUDING ANTI-ANGIOGENESIS AGENTS AND AGONISTS BINDING OX40 |
| MA51552A (en) | 2014-03-31 | 2021-03-24 | Hoffmann La Roche | ANTI-OX40 ANTIBODIES AND METHODS OF USE |
| WO2016036873A1 (en) | 2014-09-05 | 2016-03-10 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| EP3193866A1 (en) | 2014-09-19 | 2017-07-26 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
| CN107912040B (en) | 2014-10-10 | 2021-04-06 | 基因泰克公司 | Pyrrolidine amide compounds as histone demethylase inhibitors |
| CN107109484B (en) | 2014-11-03 | 2021-12-14 | 豪夫迈·罗氏有限公司 | Methods and biomarkers for efficacy prediction and assessment of OX40 agonist treatment |
| CN106796235B (en) | 2014-11-03 | 2021-01-29 | 豪夫迈·罗氏有限公司 | Assays for detecting T cell immune subsets and methods of use thereof |
| CN107073126A (en) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | Combination treatment comprising OX40 combinations activator and TIGIT inhibitor |
| MA40940A (en) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS |
| EP3218376B1 (en) | 2014-11-10 | 2019-12-25 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| MA40943A (en) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS |
| BR112017010198A2 (en) | 2014-11-17 | 2017-12-26 | Genentech Inc | combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| JP2018508183A (en) | 2014-12-23 | 2018-03-29 | ジェネンテック， インコーポレイテッド | Compositions and methods for treating and diagnosing chemotherapy-resistant cancer |
| JP2018503373A (en) | 2014-12-30 | 2018-02-08 | ジェネンテック， インコーポレイテッド | Methods and compositions for cancer prognosis and treatment |
| JP6855379B2 (en) | 2015-01-09 | 2021-04-07 | ジェネンテック， インコーポレイテッド | (Piperidin-3-yl) (naphthalene-2-yl) metanone derivatives and related compounds as inhibitors of histone demethylase KDM2B for the treatment of cancer |
| JP6659703B2 (en) | 2015-01-09 | 2020-03-04 | ジェネンテック， インコーポレイテッド | Pyridazinone derivatives and their use in the treatment of cancer |
| CN107406418B (en) | 2015-01-09 | 2021-10-29 | 基因泰克公司 | 4, 5-dihydroimidazole derivatives and their use as histone demethylase (KDM2B) inhibitors |
| WO2016123391A1 (en) | 2015-01-29 | 2016-08-04 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| CN107438593B (en) | 2015-01-30 | 2020-10-30 | 基因泰克公司 | Therapeutic compounds and uses thereof |
| MA41598A (en) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES |
| MX2017012805A (en) | 2015-04-07 | 2018-04-11 | Genentech Inc | Antigen binding complex having agonistic activity and methods of use. |
| JP7048319B2 (en) | 2015-05-12 | 2022-04-05 | ジェネンテック， インコーポレイテッド | Treatment and diagnosis methods for cancer |
| JP7144935B2 (en) | 2015-05-29 | 2022-09-30 | ジェネンテック， インコーポレイテッド | Therapeutic and diagnostic methods for cancer |
| MX2017014740A (en) | 2015-06-08 | 2018-08-15 | Genentech Inc | Methods of treating cancer using anti-ox40 antibodies. |
| MX2017015937A (en) | 2015-06-08 | 2018-12-11 | Genentech Inc | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists. |
| EP3310815A1 (en) | 2015-06-17 | 2018-04-25 | F. Hoffmann-La Roche AG | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| EP3341376B1 (en) | 2015-08-26 | 2020-12-23 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Condensed tricyclic compounds as protein kinase inhibitors |
| AU2016369528B2 (en) | 2015-12-16 | 2021-04-22 | Genentech, Inc. | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer |
| ES2837428T3 (en) | 2016-01-08 | 2021-06-30 | Hoffmann La Roche | CEA-Positive Cancer Treatment Procedures Using PD-1 Axis Binding Antagonists and Anti-CEA / Anti-CD3 Bispecific Antibodies |
| JP6821693B2 (en) | 2016-02-29 | 2021-01-27 | ジェネンテック， インコーポレイテッド | Treatment and diagnosis for cancer |
| US20170319688A1 (en) | 2016-04-14 | 2017-11-09 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
| KR20190003958A (en) | 2016-04-15 | 2019-01-10 | 제넨테크, 인크. | Treatment and monitoring of cancer |
| WO2017181079A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
| KR20180134347A (en) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | Diagnosis and Treatment of Cancer |
| JP7160688B2 (en) | 2016-05-24 | 2022-10-25 | ジェネンテック， インコーポレイテッド | Heterocyclic inhibitors of CBP/EP300 and their use in treating cancer |
| CN109476663B (en) | 2016-05-24 | 2021-11-09 | 基因泰克公司 | Pyrazolopyridine derivatives for the treatment of cancer |
| US20200129519A1 (en) | 2016-06-08 | 2020-04-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| CN109476748B (en) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | Methods for treatment and diagnosis of cancer |
| EP3523451A1 (en) | 2016-10-06 | 2019-08-14 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| JP2019535250A (en) | 2016-10-29 | 2019-12-12 | ジェネンテック， インコーポレイテッド | Anti-MIC antibody and method of use |
| MX2019010295A (en) | 2017-03-01 | 2019-11-21 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
| AU2018250875A1 (en) | 2017-04-13 | 2019-10-03 | F. Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer |
| EP3679159A1 (en) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| MX2020004567A (en) | 2017-11-06 | 2020-08-13 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
| AU2019275404A1 (en) | 2018-05-21 | 2020-12-03 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
| BR112020026384A2 (en) | 2018-06-23 | 2021-03-30 | Genentech, Inc. | METHODS FOR TREATING AN INDIVIDUAL WITH LUNG CANCER AND FOR TREATING AN INDIVIDUAL WITH SMALL CELL LUNG CANCER, KITS, ANTIBODY ANTI-PD-L1 AND COMPOSITION |
| CA3104147A1 (en) | 2018-07-18 | 2020-01-23 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
| WO2020051099A1 (en) | 2018-09-03 | 2020-03-12 | Genentech, Inc. | Carboxamide and sulfonamide derivatives useful as tead modulators |
| WO2020061060A1 (en) | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
| EP4249917A3 (en) | 2018-09-21 | 2023-11-08 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
| EP3867646A1 (en) | 2018-10-18 | 2021-08-25 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
| CN113396230A (en) | 2019-02-08 | 2021-09-14 | 豪夫迈·罗氏有限公司 | Methods of diagnosis and treatment of cancer |
| JP2022521773A (en) | 2019-02-27 | 2022-04-12 | ジェネンテック， インコーポレイテッド | Dosing for treatment with anti-TIGIT antibody and anti-CD20 antibody or anti-CD38 antibody |
| US20220146495A1 (en) | 2019-02-27 | 2022-05-12 | Epiaxis Therapeutics Pty Ltd | Methods and agents for assessing t-cell function and predicting response to therapy |
| WO2020223233A1 (en) | 2019-04-30 | 2020-11-05 | Genentech, Inc. | Prognostic and therapeutic methods for colorectal cancer |
| EP3962947A2 (en) | 2019-05-03 | 2022-03-09 | F. Hoffmann-La Roche AG | Methods of treating cancer with an anti-pd-l1 antibody |
| CN112300279A (en) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | Methods and compositions directed to anti-CD 73 antibodies and variants |
| TW202124439A (en) | 2019-09-04 | 2021-07-01 | 美商建南德克公司 | Cd8 binding agents and uses thereof |
| JP2022548978A (en) | 2019-09-27 | 2022-11-22 | ジェネンテック， インコーポレイテッド | Dosing for Treatment with Drugs Anti-TIGIT and Anti-PD-L1 Antagonist Antibodies |
| CN114728936A (en) | 2019-10-29 | 2022-07-08 | 豪夫迈·罗氏有限公司 | Bifunctional compounds for the treatment of cancer |
| MX2022005400A (en) | 2019-11-06 | 2022-05-24 | Genentech Inc | Diagnostic and therapeutic methods for treatment of hematologic cancers. |
| CA3155989A1 (en) | 2019-11-13 | 2021-05-20 | Jason Robert ZBIEG | Therapeutic compounds and methods of use |
| AU2020403145A1 (en) | 2019-12-13 | 2022-07-07 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
| AU2020408562A1 (en) | 2019-12-20 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| TW202142230A (en) | 2020-01-27 | 2021-11-16 | 美商建南德克公司 | Methods for treatment of cancer with an anti-tigit antagonist antibody |
| WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
| CN115698717A (en) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | Methods of treatment and diagnosis of cancer |
| WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
| KR20230025691A (en) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | Methods and compositions for treating triple negative breast cancer |
| WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| JP2023536602A (en) | 2020-08-03 | 2023-08-28 | ジェネンテック， インコーポレイテッド | Diagnostic and therapeutic methods for lymphoma |
| WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| MX2023003338A (en) | 2020-09-23 | 2023-06-14 | Erasca Inc | Tricyclic pyridones and pyrimidones. |
| CA3193952A1 (en) | 2020-10-05 | 2022-04-14 | Bernard Martin Fine | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| AU2022221124A1 (en) | 2021-02-12 | 2023-08-03 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
| KR20240026948A (en) | 2021-05-25 | 2024-02-29 | 에라스카, 아이엔씨. | Sulfur-containing heteroaromatic tricyclic KRAS inhibitor |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| TW202321261A (en) | 2021-08-10 | 2023-06-01 | 美商伊瑞斯卡公司 | Selective kras inhibitors |
| TW202340212A (en) | 2021-11-24 | 2023-10-16 | 美商建南德克公司 | Therapeutic compounds and methods of use |
| WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
| WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
| WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
| WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
| WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
| WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
-
1998
- 1998-11-04 CN CN98810806A patent/CN1278176A/en active Pending
- 1998-11-04 KR KR1020007004883A patent/KR20010031813A/en not_active Application Discontinuation
- 1998-11-04 HU HU0004286A patent/HUP0004286A3/en unknown
- 1998-11-04 EP EP98956600A patent/EP1039910A1/en not_active Withdrawn
- 1998-11-04 AU AU13087/99A patent/AU1308799A/en not_active Abandoned
- 1998-11-04 IL IL13562298A patent/IL135622A0/en unknown
- 1998-11-04 JP JP2000520129A patent/JP2001522802A/en active Pending
- 1998-11-04 CA CA002306155A patent/CA2306155A1/en not_active Abandoned
- 1998-11-04 WO PCT/US1998/023549 patent/WO1999024037A1/en not_active Application Discontinuation
- 1998-11-04 NZ NZ503991A patent/NZ503991A/en unknown
- 1998-11-04 BR BR9814116-3A patent/BR9814116A/en not_active IP Right Cessation
- 1998-11-04 PL PL98340800A patent/PL340800A1/en unknown
- 1998-11-05 AR ARP980105592A patent/AR016415A1/en unknown
- 1998-11-05 ZA ZA9810134A patent/ZA9810134B/en unknown
-
2000
- 2000-04-27 NO NO20002166A patent/NO20002166L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU1308799A (en) | 1999-05-31 |
| NZ503991A (en) | 2001-11-30 |
| JP2001522802A (en) | 2001-11-20 |
| EP1039910A1 (en) | 2000-10-04 |
| PL340800A1 (en) | 2001-02-26 |
| ZA9810134B (en) | 2000-05-05 |
| CN1278176A (en) | 2000-12-27 |
| NO20002166D0 (en) | 2000-04-27 |
| IL135622A0 (en) | 2001-05-20 |
| KR20010031813A (en) | 2001-04-16 |
| AR016415A1 (en) | 2001-07-04 |
| HUP0004286A3 (en) | 2002-01-28 |
| WO1999024037A1 (en) | 1999-05-20 |
| NO20002166L (en) | 2000-06-28 |
| BR9814116A (en) | 2000-10-03 |
| HUP0004286A2 (en) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2306155A1 (en) | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps | |
| CA2288705C (en) | Use of quinazoline compounds for the treatment of polycystic kidney disease | |
| JP3950337B2 (en) | Malignant tumor treatment | |
| US5929080A (en) | Method of treating polycystic kidney disease | |
| CA2196640C (en) | Substituted quinazoline derivatives | |
| US6337338B1 (en) | Heteroaryl-aryl ureas as IGF-1 receptor antagonists | |
| CN102731485B (en) | 4-(substituted benzene amino) quinazoline derivant and preparation method thereof, pharmaceutical composition and purposes | |
| MX2014007230A (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES. | |
| PT819129E (en) | PIRAZOLE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | |
| WO2016155545A1 (en) | Sulfamyl-containing 1,2,5-oxadiazole derivative, preparation method therefor and use thereof in pharmaceuticals | |
| WO2018157842A1 (en) | Use of 2-(substituted phenylamino)benzoic acid fto inhibitor in treating leukemia | |
| CN109574936B (en) | Hydroxamic acid compound with HDAC6 inhibitory activity and application thereof | |
| JP4828142B2 (en) | Novel fused pyrazolyl compounds | |
| JP2010070514A (en) | Pyrazole derivative and its pharmaceutical application | |
| CN108503604B (en) | (4-alkyl-5-acyl-2-thiazole) hydrazone derivatives and medical application thereof | |
| CN109574920B (en) | 3-nitrile-6-cyclopropyl pyridine IDO1 inhibitor and application thereof | |
| US6323209B1 (en) | Method of treating or inhibiting colonic polyps | |
| KR20050063747A (en) | 1-substituted-1,2,3-triazole derivatives, their intermediates, and method for production thereof | |
| CN114524799B (en) | HDAC inhibitor and preparation method and application thereof | |
| CN108047160B (en) | 2- (2-benzylhydrazono) -5-acylthiazole and medical application thereof | |
| CN101100466A (en) | Non-reversible protein tyrosine phosphorus acylase inhibitor and its preparation and application | |
| CN107233340B (en) | Application of aromatic ring medicine in inhibiting key transcription factor of malignant melanoma | |
| KR20010109526A (en) | Preventive or therapeutic drugs for various eosinophilia-related diseases containing chymase inhibitors as the active ingredient | |
| MXPA00004304A (en) | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps | |
| CZ20001660A3 (en) | Pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |